# Garvan Institute of Medical Research / Kinghorn Cancer Centre

Source: https://onco.cc/institutions/garvan-institute/  
OnCo record `garvan-institute` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

One of Australia's leading genomics institutes, whose Kinghorn Cancer Centre with St Vincent's pioneered genomics-guided treatment of pancreatic cancer and rare tumours.

## Summary

The Garvan Institute was founded in 1963 at St Vincent's Hospital in Darlinghurst and became a leader in medical genomics, hosting the Kinghorn Centre for Clinical Genomics and, with St Vincent's, The Kinghorn Cancer Centre, opened in 2012 as an integrated research and treatment facility. Garvan investigators led the Australian Pancreatic Cancer Genome Initiative within the International Cancer Genome Consortium (Andrew Biankin, Sean Grimmond), established the Molecular Screening and Therapeutics (MoST) programme for rare and advanced cancers with Omico, and run leading programmes in breast cancer biology, prostate cancer, single-cell and spatial genomics, and epigenetics (Susan Clark). Patients access precision oncology trials, phase 1 studies and germline genomics through the Kinghorn Cancer Centre.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Garvan; The Kinghorn Cancer Centre; St Vincent's Hospital Sydney
- City: Sydney, AU
- Type: research-institute
- Website: https://www.garvan.org.au

## Sources

- Garvan Institute: https://www.garvan.org.au
- The Kinghorn Cancer Centre (archived copy): https://web.archive.org/web/20230614152013/http://www.thekinghorncancercentre.org.au/
- Omico: https://www.omico.com.au

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Single-cell & spatial profiling](https://onco.cc/technologies/single-cell-spatial/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- terms: [Basket, umbrella, and platform trials](https://onco.cc/terms/basket-umbrella-platform/), [Rare cancers](https://onco.cc/terms/rare-cancers/)
- people: [Benjamin Kile](https://onco.cc/people/benjamin-kile/), [Louise Emmett](https://onco.cc/people/louise-emmett/), [Susan Clark](https://onco.cc/people/susan-clark/)
- key papers: [Genomic analyses identify molecular subtypes of pancreatic cancer](https://onco.cc/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/), [Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes](https://onco.cc/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/), [Whole genomes redefine the mutational landscape of pancreatic cancer](https://onco.cc/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/garvan-institute.json